遗传学 副教授
职称：副教授
学科专业：遗传学
研究方向：抗肿瘤药物的筛选，肿瘤代谢与免疫应答
电子邮箱：zhangyi25@jnu.edu.cn
个人介绍：广东省“珠江人才计划”引进青年拔尖人才。主要研究方向为抗肿瘤药物的筛选与肿瘤代谢与免疫应答。在抗肿瘤药物筛选方面，课题组建立了多种基于细胞和分子水平的高通量筛选平台，成功发现并验证了多个可逆转肿瘤耐药的小分子化合物。在肿瘤代谢与免疫应答领域，课题组研究揭示了O-糖基化、乳酸化等蛋白质翻译后修饰在调控肿瘤代谢重编程及耐药中的关键作用，并阐明了 DNA 损伤修复与先天免疫之间的联系机制。
近年来，相关成果以第一作者/通讯作者身份（含共同）在《Nature Communications》（2024，2025）《Cancer Research》（2022，2025）《Cancer Letters》（2024）《Clinical and Translational Medicine, 2021, 2篇》《Clinical Cancer Research》（2019）等国际权威期刊发表论文数十篇，论文总他引次数超过1000次。这些研究系统揭示了O-糖基化调控肿瘤耐药的分子机制、DNA 损伤修复失衡驱动肿瘤发展的关键通路，以及多种逆转耐药的小分子化合物作用靶点，为开发精准肿瘤治疗策略提供了重要的理论依据和候选靶点。
2012.9—2015.6 理学博士 遗传学专业，暨南大学
2009.9—2012.6 理学硕士 微生物与生化药学专业，暨南大学
2005.9—2009.6 理学学士 生物制药专业，河南工业大学
2025.7至今 副教授，暨南大学基础医学与公共卫生学院
2022.6—2025.6 研究助理教授，美国乔治华盛顿大学
2016.9—2022.6 博士后，美国乔治华盛顿大学
2015.9—2016.9 博士后，美国耶鲁大学
1. Yi Zhang, et al. O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer. Nature Communication, 2024 Jul 3;15(1):5597. (First Author, IF: 15.7)
2. Shuyan Zhou, Yi Zhang*, Zongzhu Li, et al. And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesis. Nature Communication, 2025 Oct 21;16(1):9313. (Co-First author and Co-corresponding author, IF: 15.7)
3. SY Zhou, Yi Zhang*, et al. Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB-Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer. Cancer Research, 2025 May 2;85(9):1708-1724. (Co-First author and Co-corresponding author, IF: 16.6)
4. Yi Zhang, J Li, Y Zhou, Z Li, C Peng, H Pei, W Zhu. And-1 Coordinates with the FANCM Complex to Regulate Fanconi Anemia Signaling and Cisplatin Resistance. Cancer Research, 2022, 82 (18): 3249–3262. (First Author, IF: 16.6)
5. Yi Zhang, H Wei, Y Zhou, Z Li, W Gou, Y Meng, W Zheng, J Li, Y Li, W Zhu. Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer. Clinical and Translational Medicine, 2021 Dec; 11(12): e649. (First Author, IF: 6.8)
6. Muhammad Jameel, Yi Zhang*, et al. TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancer. Cancer Letter, 2024 Nov 26:610:217356. (*Co-first Author, IF: 10.1)
7. J Li, Yi Zhang*, J Sun, W Zhu. Discovery and characterization of potent And‐1 inhibitors for cancer treatment. Clinical and Translational Medicine, 2021 Dec;11(12):e627. (*Co-first Author, IF: 6.8)
8. ZQ Li, W Zhou, Yi Zhang*, et al. ERK regulates HIF1α-mediated platinum resistance by directly targeting PHD2 in ovarian cancer. Clinical Cancer Research, 2019 Oct 1;25(19):5947-5960. (*Co-first Author, IF: 10.2)
9. Yi Zhang, SY Zhou, et al. miR-203 inhibits proliferation and self-renewal of leukemia stem cells by targeting survivin and Bmi-1. Sci Rep, 2016 Feb 5;6:19995. (First Author, IF: 3.9)
10. Yi Zhang, HX Chen, SY Zhou, et al. Sp1 and c-Myc modulate drug resistance of leukemia stem cells by regulating survivin expression through the ERK-MSK MAPK signaling pathway. Molecular Cancer, 2015,14:56. (First Author, IF:33.9)
《Nature Communications》《Cancer Research》杂志审稿专家
Frontiers in Bioscience-Landmark 青年编委
Frontiers in Medicine 杂志特邀编委
